Mylan Can’t Move Sanofi’s EpiPen Antitrust Suit

Law360, New York (July 13, 2017, 5:28 PM EDT) -- A New Jersey federal judge on Wednesday denied EpiPen maker Mylan’s motion to move to Kansas a lawsuit alleging that it offered rebates to insurers that refused to cover a competing Sanofi-Aventis epinephrine auto-injector.

U.S. District Judge Freda L. Wolfson rejected without comment Mylan Inc.’s contention that shifting the case to Kansas would allow Sanofi’s suit to be consolidated with a series of other class actions from buyers of the EpiPen, also alleging antitrust violations by Mylan.

The suit, filed in April, accused Mylan of sabotaging...
To view the full article, register now.

Documents

Related

Sections

Case Information

Case Title

SANOFI-AVENTIS U.S. LLC v. MYLAN INC. et al


Case Number

3:17-cv-02763

Court

New Jersey

Nature of Suit

Anti-Trust

Judge

Freda L. Wolfson

Date Filed

April 24, 2017

Law Firms

Companies

Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.